Opexa Therapeutics to Present at the 6th Annual European Life Science CEO
THE WOODLANDS, Texas -- March 4, 2013
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna™, a novel
T-cell therapy for multiple sclerosis (MS), today announced that Neil K.
Warma, President and Chief Executive Officer, will present at the 6th Annual
European Life Science CEO Forum on Tuesday, March 5, 2013, at 2:30 p.m. CET.
The conference will be held at the Hilton Zurich Airport Hotel in Zurich,
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific
cellular therapies for the treatment of autoimmune diseases such as MS. The
Company’s leading therapy, Tcelna™, is a personalized cellular immunotherapy
treatment that is in late stage clinical development for MS. Tcelna is derived
from T-cells isolated from peripheral blood, expanded ex vivo, and
reintroduced into the patients via subcutaneous injections. This process
triggers a potent immune response against specific subsets of autoreactive
T-cells known to attack myelin and, thereby, reduces the risk of relapse over
For more information, please visit the Company’s website at
Opexa Therapeutics, Inc.
Neil K. Warma
President & CEO
The Trout Group
Press spacebar to pause and continue. Press esc to stop.